Latest Swissmedic news and updates from Switzerland. AI-curated articles covering Swissmedic topics.
Switzerland's drug regulator, Swissmedic, is closely monitoring the drug Tavneos after its Japanese distributor warned doctors against new prescriptions following 20 deaths since 2021. US and European agencies are also reviewing the drug's approval amid safety concerns.
Swiss medicines regulator Swissmedic has approved Kisunla (donanemab) for early-stage Alzheimer's but not Leqembi (lecanemab), a drug already available in over 50 countries. The decision leaves Swiss patients with fewer advanced treatment options compared to many other nations.
In a landmark decision, Swiss medicines regulator Swissmedic has authorised Donanemab, the first drug in Switzerland that can slow the cognitive decline associated with early-stage Alzheimer's disease.
Swissmedic, the national regulator, has approved Donanemab (Kisunla), the first drug in Switzerland that can slow the progression of Alzheimer's disease in patients at an early stage. While patient groups welcome the news, questions remain about whether health insurance will cover the costs of the treatment.
Swiss Transfusion SRC has announced that blood donation criteria will be relaxed from February 1, expanding the pool of eligible donors. The changes, approved by Swissmedic, will allow donations from individuals who previously had blood transfusions or spent extended periods in the UK.
Swissmedic alerts public about counterfeit and unauthorized weight loss products containing harmful substances, particularly targeting misleading GLP-1 products on social media.
From trusted Swiss news outlets